SciClone Pharmaceuticals, Inc. (SCLN) to Release Earnings on Tuesday
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect SciClone Pharmaceuticals to post earnings of $0.22 per share for the quarter.
SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. The business had revenue of $44.52 million during the quarter. On average, analysts expect SciClone Pharmaceuticals to post $0.94 EPS for the current fiscal year and $1.07 EPS for the next fiscal year.
Shares of SciClone Pharmaceuticals, Inc. (SCLN) opened at 11.15 on Tuesday. The firm has a market capitalization of $581.93 million, a PE ratio of 13.75 and a beta of 1.72. SciClone Pharmaceuticals, Inc. has a 52 week low of $8.55 and a 52 week high of $11.43. The firm’s 50-day moving average is $11.10 and its 200 day moving average is $10.55.
TRADEMARK VIOLATION WARNING: “SciClone Pharmaceuticals, Inc. (SCLN) to Release Earnings on Tuesday” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/31/sciclone-pharmaceuticals-inc-scln-to-release-earnings-on-tuesday.html.
In other news, CEO Hong Zhao sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total value of $330,000.00. Following the completion of the sale, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at $330,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Lan Xie sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the sale, the vice president now directly owns 10,000 shares of the company’s stock, valued at $110,000. The disclosure for this sale can be found here. 5.16% of the stock is currently owned by corporate insiders.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.